Skip to main content
main-content
Erschienen in: Der Pneumologe 4/2015

01.07.2015 | Journal Club

Keine Vorteile durch VAT-PP gegenüber der klassischen Talkum-Pleurodese im palliativen Setting

verfasst von: Dr. P. Zardo, H. Busk, I. Kutschka

Erschienen in: Zeitschrift für Pneumologie | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Auszug

Rintoul RC, Ritchie AJ, Edwards JG, Waller DA et al (2014) Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet 384:1118–1127 …
Literatur
2.
Zurück zum Zitat Stahel RA, Weder W, Lievens Y et al (2010) Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v126–v128 PubMedCrossRef Stahel RA, Weder W, Lievens Y et al (2010) Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v126–v128 PubMedCrossRef
3.
Zurück zum Zitat Marinaccio A, Binazzi A, Cauzillo G et al (2007) Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. Eur J Cancer 43:2722–2728 PubMedCrossRef Marinaccio A, Binazzi A, Cauzillo G et al (2007) Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register. Eur J Cancer 43:2722–2728 PubMedCrossRef
4.
Zurück zum Zitat Perrot M de, Feld R, Cho BC et al (2009) Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 27(9):1413–1418 PubMedCrossRef Perrot M de, Feld R, Cho BC et al (2009) Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 27(9):1413–1418 PubMedCrossRef
5.
Zurück zum Zitat Sugarbaker DJ, Richards WG, Bueno R (2014) Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients. Ann Surg 260(4):577–580 PubMedCentralPubMedCrossRef Sugarbaker DJ, Richards WG, Bueno R (2014) Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients. Ann Surg 260(4):577–580 PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Treasure T, Lang-Lazdunski L, Waller D (2011) Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 12:763–772 PubMedCentralPubMedCrossRef Treasure T, Lang-Lazdunski L, Waller D (2011) Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 12:763–772 PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Weder W, Stahel RA, Baas P et al (2011) The MARS feasibility trial: conclusions not supported by data. Lancet Oncol 12:1093–1094 (author reply 4–5) PubMedCrossRef Weder W, Stahel RA, Baas P et al (2011) The MARS feasibility trial: conclusions not supported by data. Lancet Oncol 12:1093–1094 (author reply 4–5) PubMedCrossRef
8.
Zurück zum Zitat Cao CQ, Yan TD, Bannon PG et al (2010) A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol 5:1692–1703 PubMedCrossRef Cao CQ, Yan TD, Bannon PG et al (2010) A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol 5:1692–1703 PubMedCrossRef
9.
Zurück zum Zitat Rusch V, Baldini EH, Bueno R et al (2013) The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11–14, 2012, Boston, Mass. J Thorac Cardiovasc Surg 145:909–910 PubMedCrossRef Rusch V, Baldini EH, Bueno R et al (2013) The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11–14, 2012, Boston, Mass. J Thorac Cardiovasc Surg 145:909–910 PubMedCrossRef
10.
Zurück zum Zitat Mujoomdar AA, Sugarbaker DJ (2008) Hyperthermic chemoperfusion for the treatment of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 20:298–304 PubMedCrossRef Mujoomdar AA, Sugarbaker DJ (2008) Hyperthermic chemoperfusion for the treatment of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 20:298–304 PubMedCrossRef
Metadaten
Titel
Keine Vorteile durch VAT-PP gegenüber der klassischen Talkum-Pleurodese im palliativen Setting
verfasst von
Dr. P. Zardo
H. Busk
I. Kutschka
Publikationsdatum
01.07.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Zeitschrift für Pneumologie / Ausgabe 4/2015
Print ISSN: 2731-7404
Elektronische ISSN: 2731-7412
DOI
https://doi.org/10.1007/s10405-014-0857-x

Weitere Artikel der Ausgabe 4/2015

Der Pneumologe 4/2015 Zur Ausgabe

Mitteilungen des BdP-LV Ba-Wü

Mitteilungen des BdP BW

CME Zertifizierte Fortbildung

Lungenbeteiligung bei Lebererkrankungen

Neu im Fachgebiet Innere Medizin

Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.